scholarly journals Prisoners favour hepatitis C testing and treatment

2005 ◽  
Vol 134 (2) ◽  
pp. 243-248 ◽  
Author(s):  
S. VALLABHANENI ◽  
G. E. MACALINO ◽  
S. E. REINERT ◽  
B. SCHWARTZAPFEL ◽  
F. A. WOLF ◽  
...  
Keyword(s):  
At Risk ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Rhode Island ◽  
Major Obstacle ◽  
Female Inmates ◽  
Treatment Programme ◽  
Male And Female ◽  
Correctional Settings ◽  
Pass Through

More people with hepatitis C virus pass through incarcerated settings each year than any other venue. The goal of this study was to assess inmates' attitudes towards hepatitis C testing and treatment while incarcerated. We interviewed 153 male and female inmates at the Rhode Island Department of Corrections (RIDOC). Ninety-one per cent of inmates said they would agree to be tested for hepatitis C and 95% said that they would be willing to be treated for hepatitis C while incarcerated. Thirty-three per cent perceived themselves to be at risk for hepatitis C. Inmates were very interested in hepatitis C testing and, if indicated treatment. Inmates' attitudes towards hepatitis C testing and treatment do not pose a major obstacle to implementing comprehensive hepatitis C screening and treatment programme in correctional settings.

scholarly journals Epidemiology of Hepatitis C Virus in Pennsylvania State Prisons, 2004–2012: Limitations of 1945–1965 Birth Cohort Screening in Correctional Settings

2014 ◽  
Vol 104 (6) ◽  
pp. e69-e74 ◽  
Author(s):  
Sarah Larney ◽  
Madeline K. Mahowald ◽  
Nicholas Scharff ◽  
Timothy P. Flanigan ◽  
Curt G. Beckwith ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Birth Cohort ◽  
Correctional Settings ◽  
State Prisons

Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk

2012 ◽  
Vol 44 (6) ◽  
pp. 497-503 ◽  
Author(s):  
Alain H. Litwin ◽  
Bryce D. Smith ◽  
Mari-Lynn Drainoni ◽  
Diane McKee ◽  
Allen L. Gifford ◽  
...  
Keyword(s):  
Primary Care ◽  
At Risk ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Patients At Risk ◽  
Virus Testing

National treatment programme of hepatitis C in Egypt: Hepatitis C virus model of care

2017 ◽  
Vol 24 (4) ◽  
pp. 262-267 ◽  
Author(s):  
W. El-Akel ◽  
M. H. El-Sayed ◽  
M. El Kassas ◽  
M. El-Serafy ◽  
M. Khairy ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Treatment Programme ◽  
Model Of Care ◽  
National Treatment ◽  
Virus Model

MSM starting preexposure prophylaxis are at risk of hepatitis C virus infection

AIDS ◽  
2017 ◽  
Vol 31 (11) ◽  
pp. 1603-1610 ◽  
Author(s):  
Elske Hoornenborg ◽  
Roel C.A. Achterbergh ◽  
Maarten F. Schim van der Loeff ◽  
Udi Davidovich ◽  
Arjan Hogewoning ◽  
...  
Keyword(s):  
At Risk ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Infection ◽  
Hepatitis C Virus Infection ◽  
Preexposure Prophylaxis

scholarly journals Treatment as prevention for hepatitis C virus in Pakistan: mathematical modelling projections

BMJ Open ◽  
2019 ◽  
Vol 9 (5) ◽  
pp. e026600 ◽  
Author(s):  
Houssein H Ayoub ◽  
Laith J Abu-Raddad
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Incidence Rate ◽  
Treatment As Prevention ◽  
Treatment Programme ◽  
Annual Incidence Rate ◽  
Rate Reduction ◽  
Hcv Treatment ◽  
Age Structured ◽  
Direct Acting

ObjectiveDirect-acting antivirals have opened an opportunity for controlling hepatitis C virus (HCV) infection in Pakistan, where 10% of the global infection burden is found. We aimed to evaluate the implications of five treatment programme scenarios for HCV treatment as prevention (HCV-TasP) in Pakistan.DesignAn age-structured mathematical model was used to evaluate programme impact using epidemiological and programme indicators.SettingTotal Pakistan population.ParticipantsTotal Pakistan HCV-infected population.InterventionsHCV treatment programme scenarios from 2018 up to 2030.ResultsBy 2030 across the five HCV-TasP scenarios, 0.6–7.3 million treatments were administered, treatment coverage reached between 3.7% and 98.7%, prevalence of chronic infection reached 2.4%–0.03%, incidence reduction ranged between 41% and 99%, program-attributed reduction in incidence rate ranged between 7.2% and 98.5% and number of averted infections ranged between 126 221 and 750 547. Annual incidence rate reduction in the first decade of the programme was around 6%–18%. Number of treatments needed to prevent one new infection ranged between 4.7–9.8, at a drug cost of about US$900. Cost of the programme by 2030, in the most ambitious elimination scenario, reached US$708 million. Stipulated WHO target for 2030 cannot be accomplished without scaling up treatment to 490 000 per year, and maintaining it for a decade.ConclusionHCV-TasP is a highly impactful and potent approach to control Pakistan’s HCV epidemic and achieve elimination by 2030.

Sign in / Sign up

Export Citation Format

Share Document